Abstract
Overview
Introduction
Non-small cell lung cancer accounts for about 80% of all lung cancers. In
2008, the incidence of NSCLC is forecast to exceed 367,000 new cases in the
seven major pharmaceutical markets. The high incidence of the disease and the
large unmet need make NSCLC an attractive market for new drug development.
Scope
- Research and analysis of the NSCLC pipeline with in-depth clinical and
commercial assessment of Phase III candidates
- Seven major pharmaceutical market sales forecasts to 2017 for key pipeline
candidates incorporating product specific assumptions and events
- Segmentation and analysis of the current NSCLC pipeline by developmental
phase, drug class and developer
- Analysis of the NSCLC market potential, including identification of unmet
needs, commercial opportunities, and key trends in development
Report Highlights
Datamonitor has identified 104 drugs in the NSCLC pipeline, 15% of which are
in late-phase development. Collectively, these late-phase products have a
forecast sales potential of up to $4,056m by 2017 in the seven major
pharmaceutical markets.
Molecular targeted therapies are the focus of R&D in NSCLC, accounting for 60%
of the entire pipeline. Of the molecular targeted therapies in late-phase
development, Erbitux (cetuximab; ImClone/Merck Serono/Bristol-Myers Squibb) is
forecast to achieve the highest level of sales, with $473m by 2017.
The current late-phase pipeline is unlikely to satisfy the high level of unmet
need in the treatment of NSCLC. However, pipeline drugs are still likely to
realize notable uptake, despite offering only incremental improvements in
efficacy or toxicity.
Reasons to Purchase
- Acquire a detailed appreciation and impartial perspective of the NSCLC
pipeline
- Identify the key products in late-phase development based on sales
forecasts to 2017 and Datamonitor' s drug assessment methodology
- Identify opportunities and risks influencing R&D in NSCLC, unmet needs in
the treatment of the disease, and trends in current development
| 
View Cart
